Fulgent Genetics, Inc. (FLGT) came out with quarterly earnings of $0.07 per share, beating the Zacks Consensus Estimate of a loss of $0.23 per share. This compares to earnings of $0.15 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +130.43%. A quarter ago, it was expected that this company would post a loss of $0.19 per share when it actually produced earnings of $0.04, delivering a surprise of +121.05%.Over the last four qua ...

Butterfly Network, Inc. (BFLY) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of $0.07. This compares to a loss of $0.05 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +14.29%. A quarter ago, it was expected that this company would post a loss of $0.09 per share when it actually produced a loss of $0.06, delivering a surprise of +33.33%.Over the last four quarters, the company ...

Omnicell (OMCL) came out with quarterly earnings of $0.45 per share, beating the Zacks Consensus Estimate of $0.31 per share. This compares to earnings of $0.51 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +45.16%. A quarter ago, it was expected that this Omnicell Inc. would post earnings of $0.16 per share when it actually produced earnings of $0.26, delivering a surprise of +62.5%.Over the last four quarters, the company ...

Doximity (DOCS) closed the most recent trading day at $59.70, moving -2.13% from the previous trading session. This change lagged the S&P 500's daily loss of 0.3%. Elsewhere, the Dow saw a downswing of 0.46%, while the tech-heavy Nasdaq depreciated by 0.38%. The medical social networking site's stock has dropped by 0.55% in the past month, falling short of the Medical sector's gain of 0.76% and the S&P 500's gain of 3.64%.The investment community will be paying close attention to the earnings performance of ...

Hims & Hers Health, Inc. (HIMS) closed at $58.68 in the latest trading session, marking a +1.79% move from the prior day. The stock's performance was ahead of the S&P 500's daily gain of 0.02%. Meanwhile, the Dow experienced a drop of 0.14%, and the technology-dominated Nasdaq saw an increase of 0.33%. The stock of company has risen by 16.68% in the past month, leading the Medical sector's gain of 1.92% and the S&P 500's gain of 4.93%.The investment community will be closely monitoring the performance of Hi ...

Hims & Hers Health, Inc. (HIMS) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended June 2025. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price.The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on ...

Wall Street expects a year-over-year decline in earnings on higher revenues when Inspire Medical Systems (INSP) reports results for the quarter ended June 2025. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.The earnings report, which is expected to be released on August 4, might help the stock move higher if these key numbers are better than e ...

股价表现 - Veeva Systems最新收盘价上涨1.83%至291.25美元 表现优于标普500指数当日涨幅0.07% 但落后于纳斯达克指数0.18%的涨幅[1] - 过去一个月公司股价累计上涨2.33% 低于医疗行业2.39%的涨幅 显著落后于标普500指数5.71%的涨幅[1] 财务预测 - 下季度每股收益预计为1.9美元 同比增长17.28% 营收预计7.6761亿美元 同比增长13.52%[2] - 全年每股收益预期7.64美元 同比增长15.76% 营收预期31亿美元 同比增长12.78%[3] - 分析师预测修正反映短期业务趋势变化 正向修正通常预示良好业务前景[3] 估值指标 - 公司远期市盈率为37.42倍 高于行业平均31倍的水平[5] - PEG比率为1.61倍 显著低于医疗信息系统行业平均3.25倍的水平[6] - 公司当前Zacks评级为"买入"(Rank 2) 该评级系统历史表现优异 Rank 1股票自1988年以来年均回报达25%[5] 行业地位 - 医疗信息系统行业在Zacks行业排名中位列第73位 处于所有250多个行业的前30%分位[6] - 研究显示排名前50%的行业表现优于后50%行业 幅度达2:1[7]

Wall Street expects a year-over-year decline in earnings on lower revenues when Omnicell (OMCL) reports results for the quarter ended June 2025. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.The earnings report, which is expected to be released on July 31, might help the stock move higher if these key numbers are better than expectations. On t ...

股价表现 - 最新收盘价下跌1.44%至59.38美元 表现逊于标普500指数当日0.06%的涨幅 但优于纳斯达克指数0.39%的跌幅 [1] - 过去一个月累计上涨3.92% 跑赢医疗行业1.83%的跌幅 但落后标普500指数5.88%的涨幅 [1] 财务预期 - 预计8月7日公布季度EPS为0.31美元 同比增长10.71% 季度营收预计1.3967亿美元 同比增长10.26% [2] - 全年EPS共识预期1.46美元(同比增长2.82%) 营收预期6.2572亿美元(同比增长9.7%) [3] 估值水平 - 远期市盈率41.3倍 显著高于行业平均28.27倍 [6] - PEG比率4.48倍 高于医疗信息系统行业平均3.23倍 [6] 分析师评级 - 当前Zacks评级为3级(持有) 过去一个月EPS共识预期保持稳定 [5] - 分析师预期调整反映短期业务趋势变化 正面调整通常预示盈利前景改善 [3] 行业地位 - 所属医疗信息系统行业在Zacks行业排名中位列前33%(81/250+) 该排名前50%行业平均表现优于后50%两倍 [7]